Andere Sprachen MindBio Therapeutics Corp.

Aktien

A3EB9V

CA60256C1086

MBIO

Markt geschlossen - Canadian Securities Exchange Andere Börsenplätze 15:30:00 28.06.2024			% 5 Tage	% 1. Jan.
0,04 ^CAD	0,00 %		+14,29 %	+60,00 %

20.06.	MindBio Therapeutics Corp. berichtet Daten zur Dauerhaftigkeit von klinischen Studien der Phase 2A bei depressiven Patienten, die MB22001 testen	CI
12.06.	Mindbio Therapeutics meldet sekundäre Daten: Verbesserung der psychologischen Ergebnisse und Sicherheitsergebnisse bei depressiven Patienten aus der Phase-2A-Studie zu Depressionen	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

MindBio Therapeutics Corp. Reports Durability Data from Phase 2A Clinical Trials in Depressed Patients Testing MB22001	20.06.
MindBio Therapeutics Reports Secondary Data, Improvement of Psychological Outcomes and Safety Results in Depressed Patients from Phase 2A Depression Trial	13.06.
Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial	12.06.
MindBio Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	13.05.
MindBio Therapeutics Scientists Present Landmark Women's Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month	03.05.
Mindbio Therapeutics Corp. Announces Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3	02.05.
MindBio Therapeutics Announces Landmark Women's Health CNS Drug Trials	01.05.
MindBio Therapeutics Corp. Announces the Regulatory Approval of A Series of Clinical Trials in Women's Health Using MB22001	30.04.
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry	24.04.
MindBio Beginning Landmark Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder	20.03.
MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder	20.03.
MindBio Therapeutics Receives Final Approval to Conduct Phase 2B Trial Microdosing Mb22001 in Patients With MDD	04.03.
Mindbio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder	04.03.
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial	27.02.
MindBio Therapeutics Corp. Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial	26.02.
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial	15.02.
MindBio Therapeutics Corp. Completes World First Take Home Phase 2a Microdosing Depression Trial	14.02.
MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing Clinical Trial in Distressive Disorder	30.01.
MindBio Therapeutics Corp. CEO Provides End of Year Video Update on Phase 2 Clinical Trials	20.12.
MindBio Therapeutics Corp. Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer	31.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MindBio Therapeutics Corp.

Aktien

A3EB9V

CA60256C1086

MBIO

Andere Sprachen

Filter